ATE464885T1 - Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe - Google Patents

Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe

Info

Publication number
ATE464885T1
ATE464885T1 AT00988234T AT00988234T ATE464885T1 AT E464885 T1 ATE464885 T1 AT E464885T1 AT 00988234 T AT00988234 T AT 00988234T AT 00988234 T AT00988234 T AT 00988234T AT E464885 T1 ATE464885 T1 AT E464885T1
Authority
AT
Austria
Prior art keywords
suspension
delivery system
encapsulated
lipid source
provides
Prior art date
Application number
AT00988234T
Other languages
English (en)
Inventor
Jeff Shear
Al Kershman
Original Assignee
Shear Kershman Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/656,297 external-priority patent/US6541025B1/en
Application filed by Shear Kershman Lab Inc filed Critical Shear Kershman Lab Inc
Application granted granted Critical
Publication of ATE464885T1 publication Critical patent/ATE464885T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
AT00988234T 1999-12-30 2000-12-20 Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe ATE464885T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/476,483 US6340471B1 (en) 1999-12-30 1999-12-30 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US09/656,297 US6541025B1 (en) 1999-12-30 2000-09-06 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
PCT/US2000/034776 WO2001049272A2 (en) 1999-12-30 2000-12-20 Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals

Publications (1)

Publication Number Publication Date
ATE464885T1 true ATE464885T1 (de) 2010-05-15

Family

ID=23892036

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988234T ATE464885T1 (de) 1999-12-30 2000-12-20 Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe

Country Status (3)

Country Link
US (1) US6340471B1 (de)
AT (1) ATE464885T1 (de)
DE (1) DE60044261D1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6541025B1 (en) * 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US8088060B2 (en) * 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US20160287708A9 (en) * 2000-03-15 2016-10-06 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US9522217B2 (en) * 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
EP1365745A2 (de) * 2001-02-15 2003-12-03 King Pharmaceuticals, Inc. Stabilisierte pharmazeutische und schilddrüsenhormon-zusammensetzungen und herstellungsverfahren
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
FR2824477B1 (fr) * 2001-05-09 2005-09-09 Ethypharm Lab Prod Ethiques Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198671A1 (en) * 2001-08-10 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique plasma AUC properties
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030190359A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
US20040096498A1 (en) * 2002-04-29 2004-05-20 Alvin Kershman Oral pharmaceutical delivery system with improved sustained release
US20050245582A1 (en) * 2002-09-12 2005-11-03 The Hartz Mountain Corporation High concentration topical insecticides containing pyrethroids
US20040202696A1 (en) * 2003-04-14 2004-10-14 Cts Chemical Industries Ltd. Administration form for veterinary use
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
WO2005063156A1 (en) * 2003-12-22 2005-07-14 Shear/Kershman Laboratories, Inc. Oral peptide delivery system with improved bioavailability
US20060052676A1 (en) * 2004-09-07 2006-03-09 Yulun Wang Tele-presence system that allows for remote monitoring/observation and review of a patient and their medical records
US20060068020A1 (en) * 2004-09-24 2006-03-30 Cottrell Ian W Encapsulated pharmaceutical agents
AU2006279364A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Hyperphosphatemia in domestic animals: compositions and methods of treatment
US7955632B2 (en) * 2005-12-07 2011-06-07 Bayer B.V. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US20070128251A1 (en) * 2005-12-07 2007-06-07 Piedmont Pharmaceuticals, Inc. Process for manufacturing chewable dosage forms for drug delivery and products thereof
US7820221B2 (en) * 2006-05-19 2010-10-26 Delavau Llc Delivery of active agents using a chocolate vehicle
US7931930B2 (en) * 2006-05-19 2011-04-26 Delavau Llc Delivery of active agents using a chocolate vehicle
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100330058A1 (en) * 2009-06-24 2010-12-30 Hero Nutritionals, LLC Chewable drug
EP2488029B1 (de) 2009-09-30 2016-03-23 Acura Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur abschreckung vor missbrauch
RO125888B1 (ro) * 2010-04-01 2015-07-30 Biofarm S.A. Procedeu de obţinere a unui supliment alimentar cu vitamine şi minerale într-o bază grasă
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
MX354942B (es) * 2011-09-15 2018-03-27 Friulchem Spa Composiciones para la administración oral a animales, procedimientos de obtención de las mismas y sus usos.
BR112014024382B1 (pt) 2012-04-18 2022-08-09 SpecGx LLC Composições farmacêuticas de contenção de abuso de liberação imediata e seu processo de preparação
BR112015000320B1 (pt) 2012-07-12 2023-03-07 SpecGx LLC Composições farmacêuticas dissuasivas de abuso e seu processo de preparação
EP3446685A1 (de) 2012-11-30 2019-02-27 Acura Pharmaceuticals, Inc. Selbstregulierende freisetzung eines pharmazeutischen wirkstoffs
US10420729B2 (en) 2013-03-15 2019-09-24 R.P. Scherer Technologies, Llc Abuse resistant capsule
MX363844B (es) 2013-03-15 2019-04-05 SpecGx LLC Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional.
WO2015145461A1 (en) 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
AU2015284078B2 (en) 2014-07-03 2020-01-30 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US20160044955A1 (en) 2014-08-13 2016-02-18 R.J. Reynolds Tobacco Company Smokeless tobacco products
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US9949499B2 (en) 2015-06-02 2018-04-24 Pet Pill Pal Llc Handheld concealed pill morsel former
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
US10532046B2 (en) 2015-12-03 2020-01-14 Niconovum Usa, Inc. Multi-phase delivery compositions and products incorporating such compositions
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4684516A (en) * 1983-08-01 1987-08-04 Alra Laboratories, Inc. Sustained release tablets and method of making same
US4749575A (en) 1983-10-03 1988-06-07 Bio-Dar Ltd. Microencapsulated medicament in sweet matrix
US4581381A (en) 1983-11-14 1986-04-08 Nabisco Brands, Inc. Soft homogeneous antacid tablet
US4555399A (en) * 1983-11-18 1985-11-26 Key Pharmaceuticals, Inc. Aspirin tablet
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4797288A (en) * 1984-10-05 1989-01-10 Warner-Lambert Company Novel drug delivery system
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
JP2547995B2 (ja) * 1987-01-26 1996-10-30 昭和電工株式会社 反すう動物用粒剤及びその製造法
GR1001437B (el) 1992-11-05 1993-12-30 Aggelos Kontos Ζαχαροπλαστικό σύστημα χορηγήσεως φαρμακολογικώς δραστικών ουσιών.
GR1002668B (el) 1996-03-15 1997-04-14 N Μεθοδος προσθηκης στειρου αεριου αζωτου και φαρμακολογικως δραστικων ουσιων εις στερεο γιαουρτι.
US6241997B1 (en) 1998-03-16 2001-06-05 Smtm Group. Llc Chewable calcium supplement and method

Also Published As

Publication number Publication date
US6340471B1 (en) 2002-01-22
DE60044261D1 (de) 2010-06-02

Similar Documents

Publication Publication Date Title
ATE464885T1 (de) Verfahern zur herstellung von festen verabreichungssystemen für eingekapselte und nicht-eingekapselte pharmazeutische wirkstoffe
Sezer et al. Release characteristics of chitosan treated alginate beads: II. Sustained release of a low molecular drug from chitosan treated alginate beads
Leyva-Gómez et al. Approaches in polymeric nanoparticles for vaginal drug delivery: a review of the state of the art
US6103269A (en) Solid bodies containing active substances and a structure consisting of hydrophilic macromolecules, plus a method of producing such bodies
Panos et al. New drug delivery systems based on chitosan
US5405616A (en) Means for containing active substances, having a shell of hydrophilic macromolecules, active substances and process for preparation thereof
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
ATE428371T1 (de) Biologisch abbaubare anordnungen zur kontrollierten freigabe eingeschlossener substanzen
JPS63501290A (ja) マイクロカプセル
RU97115570A (ru) Применение неорганических аэрогелей в фармации
EA200000968A1 (ru) Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ
DE69812936D1 (de) Arzneimittel in form parenenteral verabreichbarer lipidmikropartikel
DE69812887T2 (de) Mikropartikel aus chitosan-gelatin a
WO2001049272A3 (en) Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
JPH06511423A (ja) 微粒子の調製
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
CN1407888A (zh) 双相释放药理活性物质或其它物质的薄膜形制剂
SE9704401D0 (sv) Matrix pellets for greasy, oily or sticky drug substances
SE8903503L (sv) Kombination av pseudoplastisk gel och ett partikelformat, kristallint eller frystorkat laekemedel foer parenteral administrering och ett saett att bereda en saadan kombination
ATE40292T1 (de) Verfahren zur herstellung von unilamellaren liposomen von grobem diameter, ihre pharmazeutische anwendung fuer die verkapselung von aktivem prinzip fuer die verzoegerte wirkstoffabgabe und vorrichtung hierfuer.
Subramanian Mucoadhesive delivery system: a smart way to improve bioavailability of nutraceuticals
Wang et al. Electrosprayed soft capsules of millimeter size for specifically delivering fish oil/nutrients to the stomach and intestines
SE9704400D0 (sv) Porous inorganic particles as carriers for drug substances
AR006087A1 (es) Forma de dosificación para la administración de clorhidrato de verapamil a una velocidad de liberación uniforme.
DE60018629D1 (de) Carbamazepinformulierung mit verzögerter Freigabe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties